NASDAQ · NRSNW
NeuroSense Therapeutics Ltd. Warrant financials
$0.0401−55.44%
Close Sep 25, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Diluted shares | 25.5M | 18.6M | 13.6M | 11.5M | 6.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $166.0K | $3.4M | $2.6M | $3.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.0M | $4.6M | $3.2M | $7.7M |
| Total liabilities | $2.6M | $2.0M | $4.9M | $2.1M |
| Shareholders' equity | -$1.6M | $2.6M | -$1.8M | $5.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology